Literature DB >> 6882622

The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease.

P W Serruys, G Vanhaleweyk, M Van Den Brand, P Verdouw, J Lubsen, P G Hugenholtz.   

Abstract

Flecainide acetate has been shown to be a potent antiarrhythmic agent which is active for more than 8 h, whether given intravenously or orally. However, the negative inotropic effect demonstrated in animal studies could hamper the potential clinical utility of the drug. Ten patients with coronary artery disease but without cardiac failure were given intravenous flecainide (2 mg/kg). Stroke index (SI), left ventricular systolic pressure (LVP), end diastolic pressure (EDP) and LV contractility indices (max dP/dt, VCE 40 mm Hg, peak VCE, Vmax from total pressure (TP] were measured immediately before and 10 min after flecainide, under resting conditions and during atrial pacing with heart rates up to 133 +/- 4.2 beats/min (mean +/- s.e. mean). It is demonstrated that flecainide has a negative inotropic effect, not only under resting conditions, but also less apparently during pacing-induced tachycardia. The effect appears to be dose-related and may result in a reduction of cardiac performance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882622      PMCID: PMC1427947          DOI: 10.1111/j.1365-2125.1983.tb02143.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  A computer system for real time analysis of cardiac catheterization data.

Authors:  G T Meester; N Bernard; C Zeelenberg; R W Brower; P G Hugenholtz
Journal:  Cathet Cardiovasc Diagn       Date:  1975

2.  Beat-to-beat analysis of left ventricular function parameters.

Authors:  G T Meester; C Zeelenberg; S Gorter; A C Miller; P G Hugenholtz
Journal:  Eur J Cardiol       Date:  1974-03

3.  Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation.

Authors:  S B Olsson; N Edvardsson
Journal:  Am Heart J       Date:  1981-11       Impact factor: 4.749

4.  Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

Authors:  H J Duff; D M Roden; R J Maffucci; B S Vesper; G J Conard; S B Higgins; J A Oates; R F Smith; R L Woosley
Journal:  Am J Cardiol       Date:  1981-12       Impact factor: 2.778

5.  Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.

Authors:  A B Hodess; W P Follansbee; J F Spear; E N Moore
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jul-Aug       Impact factor: 3.105

6.  Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart.

Authors:  P D Verdouw; J W Deckers; G J Conrad
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jul-Aug       Impact factor: 3.105

7.  [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].

Authors:  L Seipel; R R Abendroth; G Breithardt
Journal:  Z Kardiol       Date:  1981-07

8.  Antiarrhythmic effects of flecainide.

Authors:  P Somani
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Oral flecainide acetate for the treatment of ventricular arrhythmias.

Authors:  J L Anderson; J R Stewart; B A Perry; D D Van Hamersveld; T A Johnson; G J Conard; S F Chang; D C Kvam; B Pitt
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

10.  [Antiarrhythmic therapy with flecainide in acute experimental myocardial infarction (author's transl)].

Authors:  H Gülker; F Bender; B Brisse; J Thale; H Heuer; J Kristek; F Schindelhauer; K Teerling
Journal:  Z Kardiol       Date:  1981-02
  10 in total
  10 in total

Review 1.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

2.  Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.

Authors:  B Silke; M A Frais; S P Verma; G W Reynolds; M Hafizullah; P A Kalra; N C Jackson; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

3.  Flecainide--an intravenous infusion regimen.

Authors:  J C Cowan; D W Holt; R S Bexton; D S Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Effects of flecainide on isolated vascular smooth muscles of rat.

Authors:  F Pérez-Vizcaino; J Duarte; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

5.  Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.

Authors:  P H Dunselman; J H Kingma; L M van Wijk; A Dijk; H Wesseling; K I Lie
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  The antiarrhythmic effect of flecainide on halothane-epinephrine induced arrhythmias in dogs.

Authors:  N Iwatsuki; M Takahashi; S Satoh; T Tajima
Journal:  J Anesth       Date:  1990-10       Impact factor: 2.078

7.  Long term inotropic effects of flecainide and propafenone.

Authors:  E Henze; J Roth; W Haerer; W E Adam; M Stauch
Journal:  Eur J Nucl Med       Date:  1988

Review 8.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 9.  Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.

Authors:  Etienne Aliot; Alessandro Capucci; Harry J Crijns; Andreas Goette; Juan Tamargo
Journal:  Europace       Date:  2010-12-07       Impact factor: 5.214

Review 10.  Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.

Authors:  Juan Tamargo; Jean-Yves Le Heuzey; Phillipe Mabo
Journal:  Eur J Clin Pharmacol       Date:  2015-04-15       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.